Bioanalytical Overview Parameters Substrate History · Evolution Current 2026 Future 2026-2035 AI lens Flow of trials Players & stakeholders Notes
Library/Bioanalytical Trials/Parameters
chapter 01 · the validation spine

The nine BMV parameters · five regulators.

Quick-reference grid of all nine parameters · then the cross-regulator comparison drilldown for each. ICH M10 · FDA · EMA · WHO · ANVISA. The flagship chapter for the analytical spine.

/ 00

The deep reference: iFeed.bioanalytical.

Already published · live

iFeed maintains a deep reference for bioanalytical method validation under the sub-brand iFeed.bioanalytical. The foundation document is a cross-regulator comparison across five regulators (ICH M10 · FDA · EMA · WHO · ANVISA) and the nine BMV pillars that form the validation spine. Built on the official BMV guidelines and the production-floor substrate — bioanalytical, MedTech, and clinical-trial — assembled across CRO, sponsor, and MedTech years.

/ Foundation document

5 regulators · 9 BMV pillars · one reference.

Pick a pillar. Read the convergence/divergence summary. Compare 5 regulators side-by-side. Each acceptance criterion highlighted. Designed for the validation scientist · the QA auditor · the cross-region sponsor.

ICH M10FDAEMA Rev 1WHO TRS 996ANVISA
/ 00b

The nine BMV pillars.

The validation spine

These nine pillars are what every bioanalytical method must satisfy to be validation-complete. Below: a quick-reference grid of all nine parameters · then the cross-regulator comparison drilldown for each. Selectivity is where most novel methods fail first; matrix effect (★) is where the cross-regulator divergence runs deepest.

Quick reference · the nine parameters.

/ 3.1
Selectivity & specificity.

Can the method tell analyte apart from matrix interference? All five regulators converge on the principle; FDA & ICH M10 require 10 individual sources for LBAs.

/ 3.2
Calibration curve & range.

Six non-zero calibrators, blank, zero. ±15% nominal except LLOQ at ±20%. The autobiography of the method.

/ 3.3
Accuracy & precision.

Within-run, between-run. ±15% nominal accuracy, ≤15% CV precision. Four QC concentration levels covering the validation range.

/ 3.4
Carry-over.

Response in blank after ULOQ injection ≤20% LLOQ. Where chromatographic methods most often surprise QA.

/ 3.5
Matrix effect.★

Where regulator divergence runs deepest. ICH M10 + FDA require six lots minimum + haemolysed/hyperlipidaemic. EMA framework slightly different.

/ 3.6
Stability.

Bench-top, freeze-thaw, long-term, stock solution, processed sample. The forgotten validation activity that fails inspections years later.

/ 3.7
Dilution integrity.

For samples above ULOQ. Dilution factor up to 10× typically validated. Critical for dose-escalation and pediatric formulations.

/ 3.8
Incurred sample reanalysis (ISR).

10% of samples reanalysed in pivotal studies. ≥67% within 20% of original. The post-validation reality check.

/ 3.9
Reanalysis & in-study.

Run acceptance criteria · 75% of QCs and 67% per concentration. Authority for repeats. Documented per study.

Cross-regulator comparison · ICH M10 · FDA · EMA · WHO · ANVISA.

ICH M10 FDA EMA Rev 1 WHO TRS 996 ANVISA
/ 3.1 Selectivity & specificity.Can the method tell analyte apart from matrix interference? +
At a glance · convergence vs divergence
CONVERGE
All 5 regulators require differentiation of analyte from endogenous matrix components. Acceptance: response in blank ≤20% LLOQ analyte · ≤5% IS.
DIVERGE
FDA & ICH M10 require 10 individual sources for LBAs (vs 6 chromatographic) · EMA Rev 1 historically permitted 6 across both. ANVISA defers · WHO defers to SRA framework.
ICH M102022
§3.2.1 / §4.2.2 · harmonised
6 lots for chromatographic methods · 10 sources for LBAs (FDA-stricter rule inherited).
Acceptance criteriaBlank ≤20% LLOQ · ≤5% IS · 6 lots CC · 10 lots LBA
FDA2018
Origin of 10-source LBA rule
§III.B.4 / Table 1 · originated the 10-source LBA rule with 80% pass requirement · adopted into M10 unchanged.
Acceptance criteriaSame blank · 10 sources LBA · 80% pass · 6 lots CC
EMA Rev 12011
Superseded by M10
§4.1.1 · 6 lots historically · cover page now carries supersession notice referencing M10.
Acceptance criteriaSame blank · 6 lots across CC and LBA · superseded
WHO TRS 9962016
Annex 9 · multisource
Defers acceptance criteria to stringent regulatory authority · §20 BMV embedded in BE context.
Acceptance criteriaDefers to SRA framework
ANVISARDC 27/2012
BCN-decks-sourced · LBA n/a
Brazilian framework via Barrientos 2011 / Tavares 2012 BCN presentations · LBAs explicitly out of CP33 scope.
Acceptance criteriaGeneral principles aligned · LBA n/a
Inspector's eye
Auditors increasingly check whether LBA selectivity panels include 10 individual sources post-M10. Pre-2022 packages often used 6 (EMA-style) and now read as out-of-compliance. §4.2.2 reference is the audit-trigger keyword.
/ 3.2 Calibration curve & range.Concentration-response model · 6 non-zero levels · ±15% / ±20% LLOQ. +
At a glance · convergence vs divergence
CONVERGE
All 5 regulators converge on ±15% / ±20% LLOQ for chromatographic methods · 6 non-zero calibrators · 75% pass rate. The single most-harmonised BMV pillar.
DIVERGE
M10 §3.3.2 closes a regression-model lock loophole pre-2022 EMA practice tolerated. LBA cards have wider range tolerances (±20% / ±25% LLOQ-ULOQ).
ICH M102022
§3.3.2 closes regression loophole
CC: ±15% / ±20% LLOQ · 75% pass · 6 levels. LBA: ±20% / ±25% LLOQ-ULOQ.
Acceptance criteria±15% · ±20% LLOQ · 75% pass · 6 non-zero
FDA2018
Final · same thresholds
§III.B.2 · standard chromatographic + LBA criteria · M10-aligned at adoption.
Acceptance criteria±15% · ±20% LLOQ · 75% pass · 6 levels
EMA Rev 12011
Superseded · regression flexibility
§4.1.4 · same nominal thresholds · regression model flexibility now closed by M10.
Acceptance criteriaSame numerical thresholds · regression-lock now per M10
WHO TRS 9962016
Annex 9 · BE context
Defers to stringent regulatory authority criteria.
Acceptance criteriaDefers to SRA
ANVISA2012
RDC 27/2012 · BCN-sourced
Aligned to global numerical thresholds · Brazil-specific implementation details.
Acceptance criteria±15% · ±20% LLOQ
/ 3.3 Accuracy & precision.Within-run · between-run · LLOQ included · LBA needs 5 QC levels. +
At a glance · convergence vs divergence
CONVERGE
±15% accuracy and 15% CV precision converged across all CC methods. LBA: ±20% / 20% CV · LLOQ allowance ±25%.
DIVERGE
M10 §4.2.4.1 raised LBA validation to 5 QC levels including ULOQ (was 4 in EMA practice). FDA §IV requires 6 A&P runs for LBAs (vs 3 for CCs).
ICH M102022
§3.2.5 / §4.2.4 · raised LBA bar
CC: 3 reps × 6 lots. LBA: 5 QC levels (LLOQ · LowQC · MidQC · HighQC · ULOQ-near).
Acceptance criteriaCC: ±15% · 15% CV · LBA: ±20% · 20% CV · 5 QC
FDA2018
§IV · 6 A&P runs LBA
§IV requires 6 A&P runs for LBAs (vs 3 for CCs) · CDER+CVM stricter run minimum.
Acceptance criteria±15% / 15% CV CC · 6 runs LBA · 3 runs CC
EMA Rev 12011
Superseded · 4 LBA QC levels
§4.1.5 · 4 QC levels (LLOQ · Low · Mid · High) for LBAs · M10 raised to 5.
Acceptance criteria±15% / 15% CV · 4 LBA QC levels historically
WHO TRS 9962016
Annex 9 · defers
SRA framework deferral.
Acceptance criteriaDefers to SRA
ANVISA2012
RDC 27 · BCN-sourced
Brazilian implementation aligned to global thresholds.
Acceptance criteria±15% / 15% CV (CC) · LBA n/a
/ 3.4 Carry-over.Prevention + assessment in serial-injection workflows. +
At a glance · convergence vs divergence
CONVERGE
All converge on the threshold: response in blank after ULOQ ≤20% LLOQ analyte · ≤5% IS.
DIVERGE
ANVISA uniquely prescribes 3 blank injections (1 before · 2 after LSQ) where every other regulator says 1.
ICH M102022
§3.2.6 · 1 blank after ULOQ
Single blank after highest standard · prevention measures encouraged at method development.
Acceptance criteriaBlank after ULOQ ≤20% LLOQ · ≤5% IS
FDA2018
Aligned · single blank
Same single-blank approach · same thresholds.
Acceptance criteria≤20% LLOQ analyte · ≤5% IS
EMA Rev 12011
Superseded · same numbers
§4.1.2 · same threshold approach.
Acceptance criteria≤20% LLOQ analyte · ≤5% IS
WHO TRS 9962016
Defers
SRA framework.
Acceptance criteriaDefers to SRA
ANVISA2012
★ 3 blanks · unique rule
Prescribes 3 blank injections · 1 before · 2 after LSQ · stricter than every other regulator.
Acceptance criteria3 blanks (1 before · 2 after LSQ)
/ 3.5 Matrix effect.★M10 replaced EMA's IS-normalised MF with per-source A&P · ANVISA fixed-lot composition stands. +
At a glance · convergence vs divergence · the deepest pillar
CONVERGE
All recognise ion suppression / enhancement as the central LC-MS/MS quality concern.
DIVERGE
M10 §3.2.3 replaced EMA Rev 1 §4.1.8's IS-normalised Matrix Factor with per-source A&P (3 reps × 6 lots · ±15% / 15% CV). ANVISA mandates fixed lot composition (4 normal + 2 hyperlipidaemic + 2 hemolysed plasma · 4 normal + 2 hyperlipidaemic whole blood) · this survives outside M10.
ICH M102022
§3.2.3 · replaced EMA IS-norm MF
Per-source A&P · 3 reps × 6 individual lots · the most consequential pivot from legacy guidance.
Acceptance criteria3 × 6 lots · ±15% · 15% CV
FDA2018
Pre-M10 · per-source approach
FDA approach was already per-source A&P · adopted into M10 mostly unchanged.
Acceptance criteriaPer-source A&P · 6 lots · ±15% / 15% CV
EMA Rev 12011
★ SUPERSEDED · IS-norm MF
§4.1.8 IS-normalised Matrix Factor (MF analyte / MF IS · %CV ≤15% across 6 donor lots) · EMA-distinctive · explicitly replaced by ICH M10.
Acceptance criteriaIS-normalised MF · 15% CV across 6 lots · superseded
WHO TRS 9962016
Defers
SRA framework.
Acceptance criteriaDefers to SRA
ANVISA2012
★ Brazilian fixed lot · survives
Tavares 2012 BCN deck · plasma 4 normal + 2 hyperlipidaemic + 2 hemolysed · whole blood 4 normal + 2 hyperlipidaemic. Stricter than EMA's generic phrasing.
Acceptance criteriaPlasma: 4N + 2H + 2HMA · Blood: 4N + 2H
Inspector's eye
§3.2.3 matrix-effect protocol implementation date is the most-flagged audit finding in 2026 inspections. Pre-2022 EMA-style IS-normalised MF calculations are flagged out-of-compliance. Look for the per-source A&P table in validation reports · if absent · package needs M10 alignment.
/ 3.6 Stability.Stock · working solution · matrix · freeze-thaw · long-term · benchtop. +
At a glance · convergence vs divergence
CONVERGE
All require: stock solution · working solution · freeze-thaw · short-term and long-term storage stability. ±15% acceptance.
DIVERGE
WHO TRS 996 §4.22 alone declares printed chromatograms NOT a true copy of raw data · §24.4 mandates 24-72h freezer temperature mapping. ANVISA alone requires ±10% (not ±15%) for stock solution stability.
ICH M102022
§3.2.8 · standard stability suite
Stock · working · matrix · F/T · benchtop · long-term · processed sample stability.
Acceptance criteria±15% across all stability variants
FDA2018
Aligned · same suite
Same stability matrix · same threshold.
Acceptance criteria±15%
EMA Rev 12011
Superseded · same approach
§4.1.9 · same suite.
Acceptance criteria±15%
WHO TRS 9962016
★ §4.22 · §24.4 unique
§4.22: printed chromatograms NOT true copy of raw data. §24.4: 24-72h freezer temperature mapping for WHO/PQT inspections.
Acceptance criteria±15% · raw-data retention rules distinct
ANVISA2012
★ ±10% stock
Brazilian-distinctive: ±10% (not ±15%) for stock solutions · stricter than every other regulator on this single sub-pillar.
Acceptance criteriaStock: ±10% · matrix/F-T: ±15%
Inspector's eye
For Brazil-bound submissions · validate stock solution at ±10% · the ±15% global default fails ANVISA review. For WHO/PQT submissions · keep digital chromatographic raw data · §4.22 means printed copies are NOT acceptable.
/ 3.7 Dilution integrity.Validity for above-ULOQ samples · LBA needs 3 factors × 3 series. +
At a glance · convergence vs divergence
CONVERGE
All require validation that sample dilution doesn't bias the result · ±15% acceptance.
DIVERGE
M10 §4.2.6 requires 3 dilution factors × 3 independent series for LBAs (minimum 9 dilution preparations). ANVISA folds dilution QCs into precision/accuracy rather than separating.
ICH M102022
§3.2.7 / §4.2.6
Above-ULOQ samples must be diluted within validated range. LBA: 3 factors × 3 series.
Acceptance criteria±15% · LBA: 3 × 3 = 9 prep min
FDA2018
Aligned
Same approach.
Acceptance criteria±15%
EMA Rev 12011
Superseded
§4.1.7 · same threshold.
Acceptance criteria±15%
WHO TRS 9962016
Defers
SRA framework.
Acceptance criteriaDefers to SRA
ANVISA2012
Folds into A&P
Brazilian implementation: dilution QCs combined with precision/accuracy testing rather than separated.
Acceptance criteriaWithin A&P framework
/ 3.8 Incurred sample reanalysis (ISR).Post-2007 industry standard · 20% / 67% pass thresholds. +
At a glance · convergence vs divergence
CONVERGE
ICH M10 · FDA · EMA · WHO all converge on ISR as required · 20% within ±20% / ±30% LBA threshold · 67% pass rate.
DIVERGE
ANVISA was the 2011 holdout per Barrientos slide 12 ("trying to better understand the real purpose of this test") · now ICH-canonical.
ICH M102022
§3.3.4 · canonical
10% of clinical samples · ≥1000 samples → 10% of additional samples beyond 1000 (max 700).
Acceptance criteriaCC: ±20% / 67% · LBA: ±30% / 67%
FDA2018
Aligned · 20% / 67% rule
Same threshold approach.
Acceptance criteria20% / 67% CC · 30% / 67% LBA
EMA Rev 12011
§6 · same thresholds
Cetero data integrity findings (2008-2011) drove this section · post-2011 ISR mandatory in EMA submissions.
Acceptance criteria20% / 67%
WHO TRS 9962016
Annex 9 BE context
Required for WHO PQT-bound BE studies.
Acceptance criteriaSRA-aligned
ANVISA2012
★ Was holdout · now canonical
Barrientos 2011 slide 12 documented ANVISA's 2011 hesitation. RDC 27/2012 brought Brazil into alignment.
Acceptance criteriaNow ICH-aligned · 20% / 67%
/ 3.9 Reanalysis & in-study.When can you re-test a study sample · ANVISA narrowed to 3 reasons. +
At a glance · convergence vs divergence
CONVERGE
All require pre-defined reanalysis criteria documented in SAP/SOP · post-hoc justification rejected.
DIVERGE
ANVISA Barrientos 2011 slide 11 narrowed reanalysis to exactly 3 reasons (above-ULOQ requiring dilution · analytical problems · pre-dose ≥ LLOQ). IS response variation is notably absent. Closed list where every other regulator gives an example list.
ICH M102022
§3.3.4 · example list
Above-ULOQ · pre-dose ≥ LLOQ · IS response variation · failed run · open list with examples.
Acceptance criteriaExample list · pre-defined SOP
FDA2018
Aligned · open list
Same approach.
Acceptance criteriaExample list · pre-defined SOP
EMA Rev 12011
§5.4 · open list
Same approach.
Acceptance criteriaExample list
WHO TRS 9962016
Defers
SRA-aligned.
Acceptance criteriaSRA
ANVISA2012
★ 3 reasons · closed list
Barrientos 2011 slide 11 · exactly 3 reasons accepted: above-ULOQ requiring dilution · analytical problems · pre-dose above LLOQ. IS response variation is notably absent.
Acceptance criteria3 reasons closed · IS variation NOT accepted
Inspector's eye
For Brazil-bound submissions · the reanalysis SOP must be written to ANVISA's 3-reason closed list. If your global SOP allows IS-response-variation reanalysis · either revise it Brazil-specific or expect ANVISA findings.